These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 37144730)

  • 1. Adverse Events of SARS-CoV-2 Therapy: A Pharmacovigilance Study of the FAERS Database.
    Pannu V; Udongwo N; Imburgio S; Johal A; Mararenko A; Pozdniakova H; Amin T; Patel S; Hossain M; Mushtaq A; Liu E; Fune JM; Heaton J
    Ann Pharmacother; 2024 Feb; 58(2):105-109. PubMed ID: 37144730
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adverse Events Associated with Nirmatrelvir/Ritonavir: A Pharmacovigilance Analysis Based on FAERS.
    Li M; Zhang QS; Liu XL; Wang HL; Liu W
    Pharmaceuticals (Basel); 2022 Nov; 15(12):. PubMed ID: 36558906
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Postmarketing Reporting of Paxlovid-Related Dysgeusia: A Real-World Pharmacovigilance Study.
    Cvancara DJ; Baertsch HC; Lehmann AE; Humphreys IM; Farrell NF; Marshall TB; Bhatt NK; Abuzeid WM; Jafari A
    Otolaryngol Head Neck Surg; 2023 Jul; 169(1):55-61. PubMed ID: 36821807
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nirmatrelvir combined with ritonavir for preventing and treating COVID-19.
    Reis S; Metzendorf MI; Kuehn R; Popp M; Gagyor I; Kranke P; Meybohm P; Skoetz N; Weibel S
    Cochrane Database Syst Rev; 2022 Sep; 9(9):CD015395. PubMed ID: 36126225
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19.
    Hammond J; Leister-Tebbe H; Gardner A; Abreu P; Bao W; Wisemandle W; Baniecki M; Hendrick VM; Damle B; Simón-Campos A; Pypstra R; Rusnak JM;
    N Engl J Med; 2022 Apr; 386(15):1397-1408. PubMed ID: 35172054
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Post-marketing safety concerns with nirmatrelvir: A disproportionality analysis of spontaneous reports submitted to the FDA Adverse Event Reporting System.
    Zhuang W; Xu J; Wu Y; Yang J; Lin X; Liao Y; Wan J; Weng L; Lin W
    Br J Clin Pharmacol; 2023 Sep; 89(9):2830-2842. PubMed ID: 37170890
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oral Nirmatrelvir-Ritonavir as Postexposure Prophylaxis for Covid-19.
    Hammond J; Yunis C; Fountaine RJ; Luscan G; Burr AM; Zhang W; Wisemandle W; Soares H; Baniecki ML; Hendrick VM; Kalfov V; Pypstra R; Rusnak JM
    N Engl J Med; 2024 Jul; 391(3):224-234. PubMed ID: 39018532
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molnupiravir and Nirmatrelvir/Ritonavir: Tolerability, Safety, and Adherence in a Retrospective Cohort Study.
    Mazzitelli M; Mengato D; Sasset L; Ferrari A; Gardin S; Scaglione V; Bonadiman N; Calandrino L; Cavinato S; Trivellato S; Venturini F; Cattelan AM
    Viruses; 2023 Jan; 15(2):. PubMed ID: 36851598
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analysis of All-Cause Hospitalization and Death Among Nonhospitalized Patients With Type 2 Diabetes and SARS-CoV-2 Infection Treated With Molnupiravir or Nirmatrelvir-Ritonavir During the Omicron Wave in Hong Kong.
    Lui DTW; Chung MSH; Lau EHY; Lau KTK; Au ICH; Lee CH; Woo YC; Wong CKH; Cowling BJ
    JAMA Netw Open; 2023 May; 6(5):e2314393. PubMed ID: 37204790
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nirmatrelvir/ritonavir (Paxlovid®): French pharmacovigilance survey 2022.
    Bihan K; Lipszyc L; Lemaitre F; Dautriche A; Fédrizzi S; Atzenhoffer M; Vitores A; Page A; Lebrun-Vignes B
    Therapie; 2023; 78(5):531-547. PubMed ID: 37012153
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nirmatrelvir for Vaccinated or Unvaccinated Adult Outpatients with Covid-19.
    Hammond J; Fountaine RJ; Yunis C; Fleishaker D; Almas M; Bao W; Wisemandle W; Baniecki ML; Hendrick VM; Kalfov V; Simón-Campos JA; Pypstra R; Rusnak JM
    N Engl J Med; 2024 Apr; 390(13):1186-1195. PubMed ID: 38598573
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of SARS-CoV-2 RNA Rebound After Nirmatrelvir/Ritonavir Treatment in Randomized, Double-Blind, Placebo-Controlled Trials - United States and International Sites, 2021-2022.
    Harrington PR; Cong J; Troy SB; Rawson JMO; O'Rear JJ; Valappil TI; McGarry Connelly S; Farley J; Birnkrant D
    MMWR Morb Mortal Wkly Rep; 2023 Dec; 72(51):1365-1370. PubMed ID: 38127674
    [TBL] [Abstract][Full Text] [Related]  

  • 13. VV116 versus Nirmatrelvir-Ritonavir for Oral Treatment of Covid-19.
    Cao Z; Gao W; Bao H; Feng H; Mei S; Chen P; Gao Y; Cui Z; Zhang Q; Meng X; Gui H; Wang W; Jiang Y; Song Z; Shi Y; Sun J; Zhang Y; Xie Q; Xu Y; Ning G; Gao Y; Zhao R
    N Engl J Med; 2023 Feb; 388(5):406-417. PubMed ID: 36577095
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drug-drug interaction of Nirmatrelvir/ritonavir and tacrolimus: A potential risk disproportionality analysis of nephrotoxicity from COVID-19 reports in FAERS.
    Qin F; Wang H; Li M; Zhuo S; Liu W
    Expert Opin Drug Saf; 2023; 22(12):1321-1327. PubMed ID: 37477905
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of Huashi Baidu granule plus Nirmatrelvir-Ritonavir combination therapy in patients with high-risk factors infected with Omicron (B.1.1.529): A multi-arm single-center, open-label, randomized controlled trial.
    Yu Z; Zheng Y; Chen B; Lv J; Zhu X; Shang B; Xv Y; Tao R; Yang Y; Cong J; Li D; Wu H; Qv W; Zhang X; Xv C; Feng H; Yuan W; Gao Y
    Phytomedicine; 2023 Nov; 120():155025. PubMed ID: 37639813
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness and safety of Sanhan Huashi granules versus nirmatrelvir-ritonavir in adult patients with COVID-19: A randomized, open-label, multicenter trial.
    Zou X; Chang K; Fan G; Zheng H; Shen H; Tang L; Yang Y; Wang Y; Zhao L; Lv H; Zhou X; Shen X; Chen L; Tong X; Cao B;
    Sci Bull (Beijing); 2024 Jun; 69(12):1954-1963. PubMed ID: 38749859
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characteristics and outcomes of US Veterans at least 65 years of age at high risk of severe SARS-CoV-2 infection with or without receipt of oral antiviral agents.
    Gentry CA; Nguyen P; Thind SK; Kurdgelashvili G; Williams RJ
    J Infect; 2023 Mar; 86(3):248-255. PubMed ID: 36702309
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety Profile and Clinical and Virological Outcomes of Nirmatrelvir-Ritonavir Treatment in Patients With Advanced Chronic Kidney Disease and Coronavirus Disease 2019.
    Chan GCK; Lui GCY; Wong CNS; Yip SST; Li TCM; Cheung CSK; Sze RKH; Szeto CC; Chow KM
    Clin Infect Dis; 2023 Nov; 77(10):1406-1412. PubMed ID: 37531093
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative efficacy and safety of nirmatrelvir/ritonavir and molnupiravir for COVID-19: A systematic review and meta-analysis.
    Amani B; Akbarzadeh A; Amani B; Shabestan R; Khorramnia S; Navidi Z; Rajabkhah K; Kardanmoghadam V
    J Med Virol; 2023 Jun; 95(6):e28889. PubMed ID: 37368841
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preclinical discovery and development of nirmatrelvir/ritonavir combinational therapy for the treatment of COVID-19 and the lessons learned from SARS-COV-2 variants.
    Pagliano P; Spera A; Sellitto C; Scarpati G; Folliero V; Piazza O; Franci G; Conti V; Ascione T
    Expert Opin Drug Discov; 2023; 18(12):1301-1311. PubMed ID: 37614103
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.